This invention relates to crystalline structures of the topoisomerase I and their use in designing new anti-cancer agents and anti-microbial agents. In particular, crystal compositions comprising topoisomerase I, a duplex 22mer DNA and the inhibitors Topotecan, AG260, MJ-II-38 and Hoechst-3342 are disclosed.